Investor Presentation - First Six Months of 2021
41
Investor presentation First six months of 2021
Novo Nordisk has a strong leadership position within the
growing diabetes market
Global diabetes market by treatment class¹
Novo Nordisk remains global diabetes
value market leader
Novo Nordisk market share and
share of growth
Novo NordiskⓇ
DKK billion
350
Market CAGR²: 8.7%
35%
60%
300
30%
30%
50%
250
CAGR: 0.4%
42%
25%
40%
200
CAGR: 17.7%
20%
30%
150
CAGR: 24.9%
15%
30%
20%
100
10%
CAGR: (3.2%)
50
10%
5%
0
0%
0%
15FY
16FY
17FY
18FY
19FY
20FY
May
May
May
2011
2021
2018
May
2021
Insulin GLP-1
SGLT-2 DPP-4
Novo Nordisk
Sanofi
Merck
AstraZeneca
-Takeda
Eli Lilly
BI
NN market share
NN share of growth
-Novartis
-J&J
1 Data is based on company reported sales from Sanofi, Eli Lilly, AstraZeneca, GSK, Novartis, Johnson & Johnson, and Merck. Data does not include generic metformin, sulphonylureas or thiazolidinedione
2 CAGR for 5-year period; ; BI: Boehringer Ingelheim; J&J: Johnson & Johnson
Source: IQVIA MAT, May 2021 value figures Note: IQVIA data can be inflated due to use of list prices in the USView entire presentation